Peripheral T-cell Lymphoma, NOS

The most common PTCL subtype by exclusion — heterogeneous biology, poor outcomes with CHOP, and emerging targeted therapies guided by CD30 expression and molecular profiling

Key Points

• PTCL-NOS is the largest single subtype of peripheral T-cell lymphoma (~25–30% of all PTCL), defined by exclusion after specific PTCL entities (AITL, ALCL, ENKTL, etc.) have been ruled out by morphology, immunophenotype, and molecular studies.
• The tumor arises from mature, post-thymic CD4+ or CD8+ T cells; CD4+ predominance is more common; a minority express cytotoxic markers or have a γδ phenotype.
• Gene expression profiling has identified two major molecular subgroups — GATA3 (Th2 signature, worse prognosis) and TBX21 (Th1/cytotoxic signature, better prognosis) — which may guide future treatment stratification.
• Outcomes with standard CHOP chemotherapy are poor: 5-year OS is approximately 30–40%, and the majority of patients relapse within 2 years; this dismal prognosis drives the investigation of alternative frontline strategies.
• CHOP or CHOEP (with etoposide) remains standard for CD30-negative PTCL-NOS; brentuximab vedotin + CHP (BV+CHP) is preferred when CD30 expression is ≥10%, based on the ECHELON-2 trial.
• Consolidation with autologous stem cell transplantation in first complete remission is recommended for eligible patients; allogeneic SCT is reserved for relapsed/refractory disease.

Biology and Molecular Subgroups

PTCL-NOS is a biologically heterogeneous entity — a wastebasket category encompassing all mature T-cell lymphomas that do not fulfill criteria for a more precisely defined WHO entity. This heterogeneity is reflected in highly variable morphology (diffuse proliferation of medium-to-large pleomorphic T cells with a polymorphous inflammatory background), immunophenotype (variable CD4/CD8 expression, frequent loss of normal T-cell antigens), and clinical behavior. Gene expression profiling by Iqbal and colleagues identified two major molecular subgroups: - **GATA3 subgroup** (~40%): Activated by…

Clinical Presentation and Diagnosis

PTCL-NOS affects adults with a median age of 55–60 years, with male predominance (~60%). Patients typically present with advanced-stage disease (stage III–IV in >70%), systemic B symptoms (fever, night sweats, weight loss), generalized lymphadenopathy, and elevated LDH. Extranodal involvement is common (~60%), particularly affecting the liver, bone marrow, skin, and GI tract. Bone marrow involvement is present in approximately 30–40% of cases. A subset presents with features overlapping AITL (hypergammaglobulinemia, autoimmune phenomena) and may harbor TET2/RHOA mutations, reflecting shared…

Staging and Risk Stratification

PTCL-NOS is staged by the Lugano (Ann Arbor) classification. PET-CT is the standard staging modality. Bone marrow biopsy is required. The Prognostic Index for T-cell Lymphoma (PIT) is the most validated tool for PTCL including PTCL-NOS. It incorporates: - Age >60 - ECOG performance status ≥2 - LDH above normal - Bone marrow involvement PIT risk groups: - Score 0: 5-year OS ~62% - Score 1–2: 5-year OS ~33% - Score 3–4: 5-year OS ~18% The IPI performs similarly in most analyses. Molecular subgrouping (GATA3 vs TBX21) provides additional prognostic information beyond clinical indices. CD30…

Treatment

**First-Line Therapy** For CD30-negative PTCL-NOS (or CD30 <10%): - CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) × 6–8 cycles remains standard, though deeply inadequate - CHOEP (CHOP + etoposide) is preferred for younger patients (age <60–65) with normal LDH, based on retrospective data from the German High-Grade NHL Study Group showing improved EFS in T-cell lymphomas For CD30-positive PTCL-NOS (≥10% expression): - BV+CHP (brentuximab vedotin + cyclophosphamide, doxorubicin, prednisone) was studied in the ECHELON-2 trial, which included a subset of CD30+ PTCL-NOS; in…

Prognosis and Future Directions

PTCL-NOS carries one of the poorest prognoses among aggressive lymphomas. Five-year OS with CHOP-based therapy is approximately 30–40%, and the majority of patients relapse. The International PTCL Project demonstrated a median OS of only 5.2 years for all PTCL-NOS patients combined, with most treatment failures occurring within 2 years. The lack of a clearly effective frontline regimen distinguishes PTCL-NOS from B-cell lymphomas, where rituximab has transformed outcomes. The absence of a suitable pan-T-cell surface antigen (analogous to CD20 on B cells) has been a major obstacle; however,…